A 42-year-old man with a 10-year history of alcohol use disorder presents with jaundice, ascites, and spider angiomas. Laboratory investigations show total bilirubin 8.2 mg/dL (predominantly conjugated), AST 320 U/L, ALT 180 U/L, albumin 2.8 g/dL, and INR 2.1. Ultrasound abdomen confirms cirrhosis with portal hypertension. What is the drug of choice for primary prophylaxis of variceal bleeding in this patient?

Explanation

## Primary Prophylaxis of Variceal Bleeding in Cirrhosis **Key Point:** Non-selective beta-blockers (propranolol, nadolol, carvedilol) are the gold standard for primary prophylaxis of variceal bleeding in patients with cirrhosis and portal hypertension, regardless of whether varices are present on screening endoscopy. ### Mechanism of Action Non-selective beta-blockers reduce portal pressure by: 1. Decreasing cardiac output (β~1~ blockade) 2. Reducing splanchnic blood flow via unopposed α-adrenergic vasoconstriction (β~2~ blockade) 3. Net reduction in portal pressure gradient by 10–20% ### Indications for Primary Prophylaxis | Finding | Recommendation | |---------|----------------| | Cirrhosis + no varices | Initiate if platelet count <100,000/μL or spleen diameter >12 cm | | Cirrhosis + small varices | Always initiate | | Cirrhosis + medium/large varices | Always initiate | | Decompensated cirrhosis (ascites, encephalopathy) | Always initiate | **High-Yield:** In this patient with decompensated cirrhosis (ascites, INR 2.1, low albumin), primary prophylaxis is mandatory. ### Drug Selection **Propranolol** is preferred because: - Non-selective β-blocker (blocks β~1~ and β~2~) - Reduces both cardiac output and splanchnic vasodilation - Oral dosing: start 40 mg BD, titrate to target HR reduction of 25% or HR <55 bpm - Alternative: **Nadolol** or **Carvedilol** (carvedilol may be superior in some studies) **Clinical Pearl:** Efficacy is monitored by reduction in heart rate (target 25% decrease from baseline or absolute HR <55 bpm), not by repeat endoscopy. ### Why Not Other Options? - **Clopidogrel:** Antiplatelet agent; no role in variceal prophylaxis and increases bleeding risk - **Omeprazole:** PPI; addresses acid-related disease, not portal hypertension - **Spironolactone:** Aldosterone antagonist; used for ascites management in cirrhosis, not variceal prophylaxis [cite:Harrison 21e Ch 297]